Edwards Lifesciences Corporation (NYSE:EW), According to the latest information the short interest in Edwards Lifesciences Corp. plummeted by 8.9% or 359,964 shares. The final shorts are 1.8% of the total floated shares. The positions dropped from 4,055,716 shares on May 31,2016 to 3,695,752 on June 15,2016. According to the per-day average trading of 1,355,006 shares, the days to cover are 3. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Edwards Lifesciences Corporation (NYSE:EW): The stock opened at $96.05 on Friday but the bulls could not build on the opening and the stock topped out at $97.53 for the day. The stock traded down to $95.76 during the day, due to lack of any buying support eventually closed down at $96.04 with a loss of -3.07% for the day. The stock had closed at $99.08 on the previous day. The total traded volume was 2,346,074 shares.
The company shares have dropped -32.53% from its 1 Year high price. On Apr 27, 2016, the shares registered one year high at $112.00 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $101.00 and the 200 Day Moving Average price is recorded at $91.24.
Edwards Lifesciences Corporation (NYSE:EW) has tumbled 2.54% during the past week and has dropped 4% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.92%. Edwards Lifesciences Corporation (NYSE:EW) has underperformed the index by 1.09% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.